SG11202103143UA - Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor - Google Patents
Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptorInfo
- Publication number
- SG11202103143UA SG11202103143UA SG11202103143UA SG11202103143UA SG11202103143UA SG 11202103143U A SG11202103143U A SG 11202103143UA SG 11202103143U A SG11202103143U A SG 11202103143UA SG 11202103143U A SG11202103143U A SG 11202103143UA SG 11202103143U A SG11202103143U A SG 11202103143UA
- Authority
- SG
- Singapore
- Prior art keywords
- syndecan
- growth factor
- specific binding
- factor receptor
- binding agents
- Prior art date
Links
- 108091008794 FGF receptors Proteins 0.000 title 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 title 1
- 102000003705 Syndecan-1 Human genes 0.000 title 1
- 108090000058 Syndecan-1 Proteins 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 230000009870 specific binding Effects 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740337P | 2018-10-02 | 2018-10-02 | |
| PCT/JP2019/038750 WO2020071365A1 (en) | 2018-10-02 | 2019-10-01 | Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103143UA true SG11202103143UA (en) | 2021-04-29 |
Family
ID=70055592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103143UA SG11202103143UA (en) | 2018-10-02 | 2019-10-01 | Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220249679A1 (en) |
| EP (1) | EP3861117A4 (en) |
| JP (1) | JP2022514148A (en) |
| KR (1) | KR20210070307A (en) |
| CN (1) | CN113039271A (en) |
| AR (1) | AR116563A1 (en) |
| AU (1) | AU2019353367A1 (en) |
| BR (1) | BR112021005465A2 (en) |
| CA (1) | CA3107423A1 (en) |
| IL (1) | IL281929A (en) |
| MX (1) | MX2021003861A (en) |
| SG (1) | SG11202103143UA (en) |
| TW (1) | TW202028459A (en) |
| WO (1) | WO2020071365A1 (en) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090175866A1 (en) * | 2004-11-04 | 2009-07-09 | Avner Yayon | Treatment of b-cell malignancies |
| PT2242772E (en) * | 2007-12-26 | 2015-02-09 | Biotest Ag | Immunoconjugates targeting cd138 and uses thereof |
| JP6400470B2 (en) * | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | Multispecific Fab fusion proteins and methods of use |
| EP2785382B1 (en) * | 2011-12-02 | 2019-01-02 | IBC Pharmaceuticals, Inc. | Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors |
| ES2684950T3 (en) * | 2011-12-08 | 2018-10-05 | Biotest Ag | Uses of immunoconjugates directed to CD138 |
| KR102091297B1 (en) * | 2012-02-03 | 2020-03-20 | 에프. 호프만-라 로슈 아게 | Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine |
| EP2887965A1 (en) * | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| US9803021B2 (en) * | 2012-12-07 | 2017-10-31 | The Regents Of The University Of California | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| HUE055424T2 (en) * | 2014-03-17 | 2021-11-29 | Mitsubishi Tanabe Pharma Corp | Antibody-fynomer conjugates |
| RU2611685C2 (en) * | 2015-07-20 | 2017-02-28 | Илья Владимирович Духовлинов | Humanized monoclonal antibody specific to syndecan-1 |
| CN110546160A (en) * | 2017-02-06 | 2019-12-06 | 奥里尼斯生物科学公司 | Targeted chimeric proteins and uses thereof |
| US10722589B2 (en) * | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| US11242403B2 (en) * | 2017-04-26 | 2022-02-08 | Mitsubishi Tanabe Pharma Corporation | Syndecan-1 (CD138) binding agents and uses thereof |
| JP2021165268A (en) * | 2020-04-07 | 2021-10-14 | 田辺三菱製薬株式会社 | Pharmaceutical compositions comprising bispecific binding substances targeting syndecan-1 and fibroblast growth factor receptor |
-
2019
- 2019-10-01 MX MX2021003861A patent/MX2021003861A/en unknown
- 2019-10-01 AR ARP190102778A patent/AR116563A1/en unknown
- 2019-10-01 AU AU2019353367A patent/AU2019353367A1/en not_active Abandoned
- 2019-10-01 CA CA3107423A patent/CA3107423A1/en active Pending
- 2019-10-01 WO PCT/JP2019/038750 patent/WO2020071365A1/en active Application Filing
- 2019-10-01 SG SG11202103143UA patent/SG11202103143UA/en unknown
- 2019-10-01 CN CN201980064967.7A patent/CN113039271A/en active Pending
- 2019-10-01 BR BR112021005465-0A patent/BR112021005465A2/en unknown
- 2019-10-01 US US17/282,368 patent/US20220249679A1/en active Pending
- 2019-10-01 TW TW108135510A patent/TW202028459A/en unknown
- 2019-10-01 EP EP19869146.1A patent/EP3861117A4/en not_active Withdrawn
- 2019-10-01 KR KR1020217011453A patent/KR20210070307A/en not_active Application Discontinuation
- 2019-10-01 JP JP2021518202A patent/JP2022514148A/en not_active Withdrawn
-
2021
- 2021-03-31 IL IL281929A patent/IL281929A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020071365A1 (en) | 2020-04-09 |
| AR116563A1 (en) | 2021-05-19 |
| AU2019353367A1 (en) | 2021-02-18 |
| TW202028459A (en) | 2020-08-01 |
| JP2022514148A (en) | 2022-02-10 |
| EP3861117A1 (en) | 2021-08-11 |
| CN113039271A (en) | 2021-06-25 |
| IL281929A (en) | 2021-05-31 |
| EP3861117A4 (en) | 2023-01-11 |
| MX2021003861A (en) | 2021-09-08 |
| CA3107423A1 (en) | 2020-04-09 |
| BR112021005465A2 (en) | 2021-06-15 |
| KR20210070307A (en) | 2021-06-14 |
| US20220249679A1 (en) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL314102A (en) | Complexes targeting transferrin receptor and uses thereof | |
| IL283839A (en) | Transferrin receptor targeting peptides | |
| IL276459A (en) | Antibody variable domains targeting the nkg2d receptor | |
| IL260666B (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
| IL276978A (en) | Il-6 antibodies and fusion constructs and conjugates thereof | |
| IL281051A (en) | Immunoconjugates targeting egfr | |
| IL276497A (en) | Fibroblast binding agents and use thereof | |
| IL274121A (en) | Bispecific antibodies binding alk-1 and bmpr-2 | |
| IL287451A (en) | Biparatopic fr-alpha antibodies and immunoconjugates | |
| IL282987B (en) | Delivery constructs for transcytosis and related methods | |
| IL291486A (en) | Therapeutic conjugates | |
| IL289145A (en) | Il1rap binding proteins | |
| IL282707A (en) | Anti-tim-3 antibodies and their use | |
| IL282708A (en) | Anti-tim-3 antibodies and their use | |
| IL286238A (en) | Antibodies targeting c5ar | |
| EP3726926C0 (en) | Heating mat | |
| GB201815045D0 (en) | Bispecific antibody targeting IL-1R1 and NLPR3 | |
| SG11202111175YA (en) | Slow-release cytokine conjugates | |
| IL281929A (en) | Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor | |
| GB2589528B (en) | Enabling software distribution | |
| IL278704B1 (en) | Multilumen implant | |
| GB201912657D0 (en) | Binding members | |
| GB201902159D0 (en) | Bi-specific conjugates | |
| GB201819124D0 (en) | Bi-specific conjugates | |
| GB201908865D0 (en) | Spine binder |